Anticoagulants Market

The global anticoagulants market size was valued at USD 33.49 Billion in 2022 and is likely to reach USD 61.58 Billion by 2031, expanding at a CAGR of 10.4% during 2023 – 2031. Growing requirement of anticoagulants to minimize the risk of blood clots during medical procedures is expected to fuel the market.

Anticoagulants are medicines that are used to reduce or prevent coagulation of blood. These medicines are commonly known as blood thinners, which interrupt the natural mechanism of blood clot formation by preventing blood cells from clumping together and breaking down existing clots in the body.

Get Free Sample Report

Anticoagulants are important in medical operations, where they offer numerous benefits to patients facing dangerous healthcare risks. Thus, they are commonly used during medical procedures and surgeries, especially in cardiovascular medical conditions, such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism to minimize the risk of clotting. Non-interruption of anticoagulants during surgery increases the risk of bleeding and triggers a sequence of undesirable outcomes.

The market report finds that the COVID-19 pandemic fueled the global market. Blood coagulation complications have been observed in COVID-19 patients. This led to a surge in the utilization of anticoagulants to manage and prevent thrombotic events associated with the disease.

• According to a report published by the National Library of Medicine, a COVID-19 patient experienced a hyper-inflammation phase during the infection, reducing the natural anticoagulant production in the body. Low molecular weight heparin (LMWH) has proven useful and is massively used as an anticoagulant medicine in the treatment of COVID-19 patients to prevent blood clots.

Anticoagulants Market Dynamics

Major Drivers

Rising prevalence of cardiovascular diseases and thrombotic disorders is a major factor driving the anticoagulant market. Increasing incidence of atrial fibrillation, deep vein thrombosis, and pulmonary embolism is creating high demand for anticoagulant therapy.

Blood thinners play a critical role in cardiovascular treatment through therapy, as it includes a multi-faceted approach, due to the use of several medications. Moreover, the growing aged population and their lifestyle factors contribute to the rising burden of cardiovascular diseases. Need for effective anticoagulants becomes paramount, which further boosts the market.

• According to WHO, globally, over 17.9 million people die each year, due to cardiovascular diseases such as coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other conditions.

Increasing awareness about the importance of anticoagulant therapy in preventing and managing thrombotic disorders is anticipated to boost the demand for anticoagulants. Moreover, the ongoing innovations in drug development and delivery systems are expanding the range of anticoagulant options, which further contributes to the market growth.

Existing Restraints

Stringent regulatory frameworks for drug approval are expected to hinder the market growth in the coming years. Anticoagulant medications undergo rigorous scrutiny and evaluation by regulatory authorities to ensure their safety and efficacy.

Complex and time-consuming regulatory processes delay the introduction of anticoagulants to the market, impeding innovations and limiting treatment options. Furthermore, the evolving regulatory landscape and changing guidelines pose challenges for manufacturers to maintain compliance and adapt their products accordingly.

Emerging Opportunities

Ongoing research activities and the development of technologies are likely to create potential growth opportunities for the key players competing in the market. Advancements in understanding the mechanisms of blood clotting and identifying specific molecular targets have paved the way for developing anticoagulant medications that selectively inhibit key components during the coagulation process.

Targeted therapies aim to achieve effective anticoagulation while minimizing the risk of bleeding complications. These novel therapies hold great potential for enhancing the safety and efficacy of anticoagulant treatment to improve outcomes and reduce adverse events.

Get Free Sample Report

Scope of Anticoagulants Market Report

The report on the market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Anticoagulants Market Segment Insights

Disease Indication Segment Analysis

Based on disease indication, the anticoagulants market is divided into pulmonary embolism (PE), deep vein thrombosis (DVT), atrial fibrillation, heart attacks, and others. The heart attack segment is expected to hold a major market share during the forecast period, as anticoagulants are important to reduce the risk of myocardial infarctions for individuals who have already suffered one heart attack.

These dangerous conditions are mainly caused by blood clots in coronary arteries. Anticoagulants, including heparin and direct oral anticoagulants (DOACs), are commonly taken during heart attacks to prevent clotting and restore blood flow.

The deep vein thrombosis (DVT) segment is anticipated to register robust growth in the coming years, due to the rising incidence of existing cardiovascular conditions and incidence of blood clots formed in a deep vein.

Anticoagulant therapy is crucial in DVT treatment, as it prevents clot extension, reduces the risk of clot detachment, and lowers the likelihood of PE occurrences. The critical role of anticoagulants in preventing life-threatening complications boosts its widespread adoption in the management of DVT, which further contributes to the segment growth.

Get Free Sample Report

Route of Administration Segment Analysis

On the basis of route of administration, the market is bifurcated into oral and injectable. The oral segment is projected to expand at a considerable CAGR during the forecast period, owing to the increasing preference for oral anticoagulants among patients, due to convenience to use.

This route of intake decreases the need for injections or other invasive procedures that provide a patient-friendly approach to anticoagulant therapy.

The simplicity of oral administration allows patients to self-administer their medications without the need for healthcare assistance, which enhances patient independence and treatment adherence. Furthermore, the wide availability of oral anticoagulants in the form of tablets or capsules that are easily swallowed is likely to boost the segment.

Distribution Channel Segment Analysis

In terms of distribution channel, the anticoagulants market is fragmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment is estimated to hold a key market share during the forecast period, due to high availability of anticoagulants in hospital pharmacies.

Anticoagulants are taken only under a doctor’s consultation, as they are often risky, making them difficult to obtain in retail pharmacies. Hospital pharmacies have wide access to all types of medicines, thus, they are able to fulfill the growing demand for anticoagulants.

The online pharmacies segment is expected to grow at a rapid pace in the coming years, owing to their direct-to-consumer delivery model and affordable prices as compared to other options. Online pharmacies minimize the requirement to visit the pharmacy store. Furthermore, the hassle-free and seamless medicine-buying options, easy access, and doorstep delivery are likely to fuel the segment.

Drug Class Segment Analysis

Based on drug class, the market is classified as novel oral anticoagulants, heparin, warfarin, direct thrombin inhibitors, heparin & low molecular weight heparin, vitamin K antagonist, and others.

The novel oral anticoagulants (NOACs) segment is projected to expand at a significant CAGR during the forecast period, owing to the high adoption of this medication in developing countries. Clinical studies have shown the demonstration of the efficacy of NOACs in lowering the incidence of bleeding as compared to other options. This grade of medicine is safe, which makes it a preferred choice.

Get Free Sample Report

Regional Outlook

In terms of region, the global anticoagulants market is segmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market in the coming years, as a considerable proportion of the population in the region suffers from cardiovascular diseases, including atrial fibrillation and venous thromboembolism.

This type of condition requires anticoagulant therapy for patient safety. Aging population in the region has unhealthy dietary habits and stressful lifestyles, which contribute to the rising prevalence of heart conditions. This increases the need for anticoagulant medicines and significantly fuels the market in the region.

• According to the Centers for Disease Control and Prevention, heart disease is the leading cause of death in the US and one person dies every 33 seconds, due to cardiovascular disease.

The market in Asia Pacific is anticipated to expand at a rapid pace in the coming years, due to the rising incidence of heart attacks. The region is registering a massive rise in chronic disorders, due to changing lifestyles, high consumption of unhealthy diets, and rapid pollution. Growing number of diseases thrust the market growth in this region and create significant demand for anticoagulants.

• According to the Indian Heart Association, about 50% of all heart attacks in Indian men occur under the age of 50.

  Get Free Sample Report
  

Segments

The global anticoagulants market has been segmented on the basis of

Disease Indication

• Pulmonary Embolism
• Deep Vein Thrombosis
• Atrial Fibrillation
• Heart Attacks
• Others

Route of Administration

• Oral
• Injectable

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Drug Class

• Novel Oral Anticoagulants
• Heparin
• Warfarin
• Direct Thrombin Inhibitors
• Heparin & Low Molecular Weight Heparin
• Vitamin K Antagonist
• Others

Region

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Aspen Holdings
• Bayer AG
• Boehringer Ingelheim International GmbH.
• Teva Pharmaceutical Industries Ltd.
• Bristol-Mayers Squibb company
• DAIICHI SANKYO COMPANY, LIMITED.
• Eisai Co., Ltd.
• GlaxoSmithKline plc.
• Janssen pharmaceuticals
• Pfizer Inc.
• Alexion Pharmaceuticals, Inc.
• Sanofi

Competitive Landscape

Key players competing in the global anticoagulants market are Aspen Holdings; Bayer AG; Boehringer Ingelheim International GmbH.; Bristol-Mayers Squibb company; DAIICHI SANKYO COMPANY, LIMITED.; Eisai Co., Ltd.; GlaxoSmithKline plc.; Janssen pharmaceuticals; Pfizer Inc.; Alexion Pharmaceuticals, Inc.; Sanofi; and Teva Pharmaceutical Industries Ltd.

These companies are boosting their market share by adopting various strategies such as partnerships, mergers, reduction in production costs, launch of products, and implementation of advanced technologies. For instance,

• On August 28, 2022, Bayer, a Germany-based multinational pharmaceutical and biotechnology company, announced the start of Phase III clinical trials to check the efficacy and safety of asundexian, an oral actor XIa (FXIa) inhibitor, as an anticoagulant. This treatment is expected to help patients who suffer from non-cardioembolic ischemic stroke and high-risk transient ischemic attack.